{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:34:42Z","timestamp":1779150882358,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Remdesivir is widely used for the management of COVID-19 and several studies have reported bradycardia as a potential side effect associated with this agent. The aim of the present study was to evaluate the incidence rate, severity, and potential risk factors of remdesivir-associated bradycardia.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed a retrospective cohort study among hospitalized adult patients with COVID-19 who were treated with remdesivir from March 2020 to October 2021. Our primary outcome of interest was the incidence rate and severity of bradycardia after remdesivir administration. We defined mild bradycardia as a heart rate of 51\u201359 beats per minute, moderate bradycardia as a heart rate of 41\u201350 beats per minute, and severe bradycardia as a heart rate of \u226440 beats per minute. We also performed univariable and multivariable regression analyses to determine potential bradycardia risk factors. Baseline characteristics were reported as means with standard deviations or medians with interquartile ranges (IQRs). All the statistical tests are shown as odds ratios (ORs) with 95% confidence intervals (CIs).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 1,635 patients were included in this study. The median age with IQR was 68 (57\u201379) years and 51.7% of the patients were male. In total, 606 (37.1%) patients developed bradycardia. Among them, 437 patients (26.7%) developed mild bradycardia, 158 patients (9.7%) moderate bradycardia, while 11 patients (0.7%) experienced severe bradycardia. In our adjusted multivariate logistic regression, the odds of bradycardia development after remdesivir administration were higher among patients with age \u226565\u00a0years (OR 1.76, 95% CI: 1.04\u20132.99, <jats:italic>p<\/jats:italic> = 0.04), those with hypertension (OR 1.37, 95% CI: 1.07\u20131.75, <jats:italic>p<\/jats:italic> = 0.01), and obesity (OR 1.32, 95% CI: 1.02\u20131.68, <jats:italic>p<\/jats:italic> = 0.03).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> More than 1 out of 3 patients (37%) who received remdesivir for COVID-19 developed bradycardia with the majority of these patients developing mild or moderate bradycardia that is usually a benign manifestation not needing treatment in most cases. Age \u226565\u00a0years, hypertension, and obesity were potential risk factors for remdesivir-associated bradycardia among hospitalized COVID-19 patients. Clinicians should be aware of this adverse event and consider close clinical monitoring for patients at high risk for this adverse event.<\/jats:p>","DOI":"10.3389\/fphar.2023.1106044","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:36:34Z","timestamp":1675258594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Yazed Saleh","family":"Alsowaida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Shehadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markos","family":"Kalligeros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jama.2022.2411","article-title":"The COVID heart-one year after SARS-CoV-2 infection, patients have an array of increased cardiovascular risks","volume":"327","author":"Abbasi","year":"2022","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e009811","DOI":"10.1161\/CIRCEP.121.009811","article-title":"Remdesivir-Induced bradycardia in COVID-19: A single center prospective study","volume":"14","author":"Attena","year":"2021","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/1573402118666220407093332","article-title":"ACEi\/ARB and deaths of COVID-19 patients","volume":"18","author":"Azad","year":"2022","journal-title":"Curr. Hypertens. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B5","volume-title":"Infectious diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 [online]","author":"Bhimraj","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"583331","DOI":"10.3389\/fmed.2020.583331","article-title":"Assessment of hypertension using clinical electrocardiogram features: A first-ever review","volume":"7","author":"Bird","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/postgradmedj-2021-141079","article-title":"Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: A retrospective cohort study on 473 patients from a tertiary centre","volume":"98","author":"Bistrovic","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/eurheartj\/ehy808","article-title":"Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET\/TRANSCEND trials","volume":"41","author":"Bohm","year":"2020","journal-title":"Eur. Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ijid.2021.09.036","article-title":"Safety and heart rate changes in Covid-19 patients treated with Remdesivir","volume":"112","author":"Brunetti","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12879-021-06300-7","article-title":"Risk factors for mortality in critically ill patients with COVID-19: A multicenter retrospective case-control study","volume":"21","author":"Gao","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B12","volume-title":"Remdesivir","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3389\/fphys.2018.01669","article-title":"Diabetes and arrhythmias: Pathophysiology, mechanisms and therapeutic outcomes","volume":"9","author":"Grisanti","year":"2018","journal-title":"Front. Physiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: Review of Pharmacology, pre-clinical data, and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/heartjnl-2020-317056","article-title":"Cardiovascular manifestations and treatment considerations in COVID-19","volume":"106","author":"Kang","year":"2020","journal-title":"Heart"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1161\/CIR.0000000000000628","article-title":"2018 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A report of the American College of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12012-021-09703-9","article-title":"Potential cardiotoxic effects of remdesivir on cardiovascular system: A literature review","volume":"22","author":"Nabati","year":"2022","journal-title":"Cardiovasc Toxicol."},{"key":"B18","volume-title":"COVID-19 treatment guideline","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jinf.2021.05.025","article-title":"Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)","volume":"83","author":"Pallotto","year":"2021","journal-title":"J. Infect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40256-022-00547-4","article-title":"Remdesivir-induced bradycardia is not associated with worse outcome in patients with COVID-19: A retrospective analysis","volume":"22","author":"Pantazopoulos","year":"2022","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/FJC.0b013e3181e0f8b2","article-title":"The mechanism of the negative chronotropic and dromotropic actions of adenosine 5'-triphosphate in the heart: An update","volume":"56","author":"Pelleg","year":"2010","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","article-title":"Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American heart association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism","volume":"113","author":"Poirier","year":"2006","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40261-022-01187-x","article-title":"Clinical characteristics and implications of bradycardia in COVID-19 patients treated with remdesivir: A single-center retrospective cohort study","volume":"42","author":"Schreiber","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1021\/acschemneuro.1c00353","article-title":"Neurological manifestations in COVID-19 patients: A meta-analysis","volume":"12","author":"Sharma","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/14740338.2021.1962846","article-title":"Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data","volume":"20","author":"Singh","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e14515","DOI":"10.1111\/ijcp.14515","article-title":"Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis","volume":"75","author":"Srivastava","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.hfc.2011.08.011","article-title":"Aging-associated cardiovascular changes and their relationship to heart failure","volume":"8","author":"Strait","year":"2012","journal-title":"Heart Fail Clin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/medicina58070950","article-title":"Bradycardia and heart rate fluctuation are associated with a prolonged intensive care unit stay in patients with severe COVID-19","volume":"58","author":"Tajarernmuang","year":"2022","journal-title":"Med. Kaunas."},{"key":"B29","doi-asserted-by":"publisher","first-page":"174579","DOI":"10.1016\/j.ejphar.2021.174579","article-title":"Use of steroids in COVID-19 patients: A meta-analysis","volume":"914","author":"Thakur","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): A new safety concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jcrc.2017.09.008","article-title":"National Early Warning Score (NEWS) at ICU discharge can predict early clinical deterioration after ICU transfer","volume":"43","author":"Uppanisakorn","year":"2018","journal-title":"J. Crit. Care"},{"key":"B32","volume-title":"Therapeutics and COVID-19 guidelines","year":""}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1106044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:36:38Z","timestamp":1675258598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1106044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":32,"alternative-id":["10.3389\/fphar.2023.1106044"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1106044","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"article-number":"1106044"}}